{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-022971","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.813106+00:00","generated_at":"2026-05-17T15:16:40.963817+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Harrow Q2 revenue $63.7M (+30% YoY); net income $5M; VEVYE on track for >$100M; adds Samsung Bioepis","bullets":["Total revenues $63.7M, up 30% YoY; GAAP net income $5.0M vs loss of $6.5M; Adj EBITDA $17.0M (up from $8.8M).","VEVYE dry eye revenue on track to exceed $100M in 2025; Q2 market share 7.8%; 66% sequential prescription growth.","IHEEZO revenue $18.3M (+62% YoY, +251% QoQ); TRIESENCE added 870 new accounts YTD; unit growth 32% QoQ.","Secured exclusive U.S. rights to Samsung Bioepis ophthalmic biosimilars (BYOOVIZ, OPUVIZ) in July 2025.","Acquired U.S. rights for BYQLOVI (clobetasol) in June 2025; Apollo Care alliance to expand VEVYE access."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-022971","json":"https://secwatch.observer/filing/0001641172-25-022971.json","markdown":"https://secwatch.observer/filing/0001641172-25-022971.md","text":"https://secwatch.observer/filing/0001641172-25-022971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225022971/0001641172-25-022971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225022971/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:16:40.963817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}